Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

99 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Towards a mechanism-based approach for the prediction of nongenotoxic carcinogenic potential of agrochemicals.
Heusinkveld H, Braakhuis H, Gommans R, Botham P, Corvaro M, van der Laan JW, Lewis D, Madia F, Manou I, Schorsch F, Wolterink G, Woutersen R, Corvi R, Mehta J, Luijten M. Heusinkveld H, et al. Among authors: van der laan jw. Crit Rev Toxicol. 2020 Oct;50(9):725-739. doi: 10.1080/10408444.2020.1841732. Epub 2020 Nov 25. Crit Rev Toxicol. 2020. PMID: 33236972 Review.
A comprehensive view on mechanistic approaches for cancer risk assessment of non-genotoxic agrochemicals.
Luijten M, Corvi R, Mehta J, Corvaro M, Delrue N, Felter S, Haas B, Hewitt NJ, Hilton G, Holmes T, Jacobs MN, Jacobs A, Lamplmair F, Lewis D, Madia F, Manou I, Melching-Kollmuss S, Schorsch F, Schütte K, Sewell F, Strupp C, van der Laan JW, Wolf DC, Wolterink G, Woutersen R, Zvonar Z, Heusinkveld H, Braakhuis H. Luijten M, et al. Among authors: van der laan jw. Regul Toxicol Pharmacol. 2020 Dec;118:104789. doi: 10.1016/j.yrtph.2020.104789. Epub 2020 Oct 7. Regul Toxicol Pharmacol. 2020. PMID: 33035627 Free article. Review.
Animal-free applications in the development of cell-based therapies.
van Meer P, Theunissen P, van den Hoorn T, Herberts C, van der Laan JW. van Meer P, et al. Among authors: van der laan jw. Br J Clin Pharmacol. 2021 Jun;87(6):2425-2427. doi: 10.1111/bcp.14544. Epub 2020 Sep 15. Br J Clin Pharmacol. 2021. PMID: 32935350 No abstract available.
Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls.
Giannakou C, Park MVDZ, Bosselaers IEM, de Jong WH, van der Laan JW, van Loveren H, Vandebriel RJ, Geertsma RE. Giannakou C, et al. Among authors: van der laan jw. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Sep;12(5):e1633. doi: 10.1002/wnan.1633. Epub 2020 Apr 7. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020. PMID: 32266791 Free PMC article. Review.
Shared Learnings on the New EMA First-in-Human and Early Clinical Trial Guideline: Proceedings From a DIAlogue Session at DIA Europe 2018.
van der Laan JW, Benson CT, Janssens W, Bos J, Stahl E, Brady JT, Wändel-Liminga U, Corriol-Rohou S, Forster R, Hartmann A, Pertel PE, Robertson SM, Silva-Lima B, Malik RE, Chibout SD. van der Laan JW, et al. Ther Innov Regul Sci. 2020 Mar;54(2):462-467. doi: 10.1007/s43441-019-00077-3. Epub 2020 Jan 6. Ther Innov Regul Sci. 2020. PMID: 32072587 Clinical Trial.
Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider.
Sato Y, Bando H, Di Piazza M, Gowing G, Herberts C, Jackman S, Leoni G, Libertini S, MacLachlan T, McBlane JW, Pereira Mouriès L, Sharpe M, Shingleton W, Surmacz-Cordle B, Yamamoto K, van der Laan JW. Sato Y, et al. Among authors: van der laan jw. Cytotherapy. 2019 Nov;21(11):1095-1111. doi: 10.1016/j.jcyt.2019.10.001. Epub 2019 Nov 9. Cytotherapy. 2019. PMID: 31711733 Free article. Review.
99 results